CLAIM #22834 · EMR (EMR) · 2025Q2 earnings call · May 7, 2025 · due Dec 31, 2028
“We expect the transaction to be modestly accretive to adjusted EPS in 2025, and we are targeting $100 million of cost synergies by 2028, primarily through the harmonization of corporate costs and G&A as well as R&D productivity.”
Lal Karsanbhai · CEO
How to check this claim
Look at: Cumulative cost synergies realized from AspenTech transaction (corporate cost/G&A and R&D productivity harmonization), as disclosed by management
It came true if: Reported run-rate cost synergies >= $100 million by fiscal year-end 2028
Where: Company management commentary / investor presentations (earnings calls, 10-K) disclosing AspenTech integration synergy progress
In context
“we expect to fully mitigate. Ram Krishnan will walk through the details in a few slides. Emerson had an excellent first half, and we are confident in our plans for the year. We are guiding underlying sales growth of approximately 4% and raising the midpoint of our adjusted EPS guide, now expecting between $5.90 to $6.05 per share. Our free cash flow guidance is $3.1 billion to $3.2 billion reflecting good performance and costs related to the AspenTech transaction, and we now expect to return $2.3 billion to shareholders through dividend and share repurchase. We're also marking the completion of the portfolio transformation we began in 2021. On March 12, we completed the buy in of AspenTech, which now operates as an independent business unit within our Control Systems and Software segment. We expect the transaction to be modestly accretive to adjusted EPS in 2025, and we are targeting $100 million of cost synergies by 2028, primarily through the harmonization of corporate costs and G&A as well as R&D productivity. Integrating AspenTech is a key priority in 2025, and the organization is energized by the future opportunities with Emerson as we accelerate to double digit ACV growth. Additionally, we have completed the integration of Test and Measurement and have executed all actions to achieve $200 million run rate cost synergies by the end of 2025. We are thankful for the hard work performed by our teams, and we will continue advancing operational excellence as this business returns to growth. Finally, following a strategic review of our Safety and Productivity business, which began in November, we concluded the best value for our shareholders is to retain the business. Safety and Productivity comprises approximately 8% of sales with market leading profitability and cash generation. This business is”
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2025Q2 earnings call.